ADVERTISEMENT

Conference Report

EAS 2022 — Do we really need injectable lipid-lowering therapies for CVD prevention?

Pavankumar Kamat   |   27 May 2022

In an interesting debate session at the European Atherosclerosis Society (EAS) 2022, Michal Vrablík, Czech Republic, and Ulrich Laufs, Germany, argued whether oral lipid-lowering therapies such as statins and ezetimibe are sufficient for cardiovascular disease (CVD) prevention or whether we need the support of injectables, i.e, proprotein convertase subtilisin/kexin type...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right